– Patent covers the Composition of the Company’s Proprietary Linea™ RNAP, a Core Technology Empowering the Linea™ IVT Platform – – Patent Application Also Currently Pending in Key International Markets – STONY BROOK, N.Y., – June 5, 2024 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the “Company”), a leader in PCR-based DNA […]
STONY BROOK, N.Y., and PRAGUE, Czechia – May 13, 2024 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA), a leader in PCR-based DNA technologies, and the Institute of Hematology and Blood Transfusion (ÚHKT/IHBT) today announced that an abstract relating to the development of a fully enzymatic, non-viral manufacturing workflow to enable the rapid and […]
Award Seeks to Demonstrate Feasibility of Manufacturing mRNA Vaccines in Only 7 Days STONY BROOK, N.Y., April 25, 2024 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced the award of a contract from HDT Bio for the purpose of rapid, next-generation vaccine development under a ‘Project NextGen: Enabler’ award to HDT […]
Project To Increase RNAP Manufacturing Capacity and Reduce Unit Costs of Goods Project Slated For Completion Coincident with Company’s Planned Initiation of GMP Manufacturing for Linea™ DNA IVT Templates STONY BROOK, N.Y., and JUPITER, F.L. March 18, 2024 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the Company), a leader in PCR-based DNA […]
STONY BROOK, N.Y., March 14, 2024 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA), a leader in PCR-based DNA technologies, will showcase its Linea™ IVT and Linea™ DNA platforms at the 24th Annual World Vaccine Congress, which will be held April 1 – 4, 2024. Applied DNA sales team members will be available during the Congress […]
Agreement Seeks to Leverage Linea IVT Platform to Enable Kudo Bio to Offer a Differentiated mRNA Manufacturing Capability with Mitigated dsRNA and Reduced Turnaround Times STONY BROOK, N.Y., and NEEDHAM, M.A. – December 14, 2023 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA), a leader in PCR-based DNA technologies, and Kudo Biotechnology (Kudo Bio), […]
STONY BROOK, N.Y. November 28, 2023 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, today announced the receipt of a follow-on order for Linea™ DNA valued above the mid-six figures. The order was placed under a long-standing supply agreement for the bulk manufacture of Linea […]
– Extension Increases Total Addressable Market to Include Both Conventional Non-Amplifying mRNA and saRNA – – Extension Enabled by the Company’s Ongoing Platform Development and Optimization – STONY BROOK, N.Y. November 16, 2023 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, announced the expansion of its […]
Preclinical Orders for Additional Customers Underway STONY BROOK, N.Y. November 9, 2023 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, today announced that it has successfully manufactured and shipped its first research use only quantity of self-amplifying mRNA (saRNA) template generated by its Linea™ DNA […]
